resminostat and Lymphoma--T-Cell--Cutaneous

resminostat has been researched along with Lymphoma--T-Cell--Cutaneous* in 1 studies

Other Studies

1 other study(ies) available for resminostat and Lymphoma--T-Cell--Cutaneous

ArticleYear
Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.
    PloS one, 2021, Volume: 16, Issue:3

    The combination of JAK/STAT and HDAC inhibitors exerted beneficial effects in haematological malignancies, presenting promising therapeutic CTCL targets. We aim to investigate the efficacy of JAK1/2i ruxolitinib in combination with HDACi resminostat in CTCL in vitro.. Non-toxic concentrations of ruxolitinib and/or resminostat were administered to MyLa (MF) and SeAx (SS) cells for 24h. Cytotoxicity, cell proliferation and apoptosis were estimated through MTT, BrdU/7AAD and Annexin V/PI assay. Multi-pathway analysis was performed to investigate the effect of JAK1/2i and/or HDACi on JAK/STAT, Akt/mTOR and MAPK signalling pathways.. Both drugs and their combination were cytotoxic in MyLa (p<0.05) and in SeAx cell line (p<0.001), inhibited proliferation of MyLa (p<0.001) and SeAx (p<0.001) at 24h, compared to untreated cells. Moreover, combined drug treatment induced apoptosis after 24h (p<0.001) in MyLa, and SeAx (p<0.001). The combination of drugs had a strong synergistic effect with a CI<1. Importantly, the drugs' combination inhibited phosphorylation of STAT3 (p<0.001), Akt (p<0.05), ERK1/2 (p<0.001) and JNK (p<0.001) in MyLa, while it reduced activation of Akt (p<0.05) and JNK (p<0.001) in SeAx.. The JAKi/HDACi combination exhibited substantial anti-tumor effects in CTCL cell lines, and may represent a promising novel therapeutic modality for CTCL patients.

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous; MAP Kinase Signaling System; Neoplasm Proteins; Nitriles; Pyrazoles; Pyrimidines; Sulfonamides

2021